Downregulation of lncRNA‑SRA participates in the development of cardiovascular disease in type II diabetic patients

Ren,Shuang; Zhang,Yi; Li,Bixun; Bu,Kunpeng; Wu,Lili; Lu,Yang; Lu,Yanyan; Qiu,Ye

doi:10.3892/etm.2019.7362

Downregulation of lncRNA‑SRA participates in the development of cardiovascular disease in type II diabetic patients

Authors:
- Shuang Ren
- Yi Zhang
- Bixun Li
- Kunpeng Bu
- Lili Wu
- Yang Lu
- Yanyan Lu
- Ye Qiu
View Affiliations

Affiliations: Department of General Internal Medicine, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China, Department of Internal Medicine-Cardiovascular, Nanning Second People's Hospital, Nanning, Guangxi 530031, P.R. China
Published online on: March 7, 2019 https://doi.org/10.3892/etm.2019.7362
Pages: 3367-3372
Copyright: © Ren et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Long non‑coding RNA steroid receptor RNA activator (lncRNA‑SRA) has been proven to regulate vascular smooth muscle cell (VSMC) proliferation, indicating its possible involvement in cardiovascular disease. Diabetes is a major cause of cardiovascular disease. The aim of the present study was to investigate the involvement of lncRNA‑SRA in type II diabetic cardiovascular disease. The plasma levels of lncRNA‑SRA were identified to be significantly lower in patients with type II diabetic cardiovascular disease compared with those in type II diabetic patients without any obvious complications and in healthy controls. A 5‑year follow‑up study revealed that low vs. high expression levels of lncRNA‑SRA were associated with an increased incidence of cardiovascular disease in type II diabetic patients. High‑glucose treatment did not significantly affect the expression of lncRNA‑SRA in human VSMCs in vitro. However, ectopic overexpression of lncRNA‑SRA increased the viability of human VSMCs in a high‑glucose environment. It was concluded that downregulation of lncRNA‑SRA may participate in the development of cardiovascular disease in type II diabetic patients.

View Figures

View References

1	Wild S, Roglic G, Green A, et al: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes care. 27:1047–1053. 2004. View Article : Google Scholar : PubMed/NCBI
2	van Dieren S, Beulens JW, van der Schouw YT, Grobbee DE and Neal B: The global burden of diabetes and its complications: An emerging pandemic. Eur J Cardiovasc Prev Rehabil. 17 (Suppl 1):S3–S8. 2010. View Article : Google Scholar : PubMed/NCBI
3	Gæde P, Vedel P, Larsen N, Jensen GV, Parving HH and Pedersen O: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 348:383–393. 2003. View Article : Google Scholar : PubMed/NCBI
4	Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V and Fuller JH; CARDS investigators, : Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet. 364:685–696. 2004. View Article : Google Scholar : PubMed/NCBI
5	Ruan Y, Lin N, Ma Q, Chen R, Zhang Z, Wen W, Chen H and Sun J: Circulating LncRNAs analysis in patients with type 2 diabetes reveals novel genes influencing glucose metabolism and Islet β-cell function. Cell Physiol Biochem. 46:335–350. 2018. View Article : Google Scholar : PubMed/NCBI
6	Esteller M: Non-coding RNAs in human disease. Nat Rev Genet. 12:861–869. 2011. View Article : Google Scholar : PubMed/NCBI
7	Liu JY, Yao J, Li XM, Song YC, Wang XQ, Li YJ, Yan B and Jiang Q: Pathogenic role of lncRNA-MALAT1 in endothelial cell dysfunction in diabetes mellitus. Cell Death Dis. 5:e15062014. View Article : Google Scholar : PubMed/NCBI
8	Li X, Wang H, Yao B, Xu W, Chen J and Zhou X: lncRNA H19/miR-675 axis regulates cardiomyocyte apoptosis by targeting VDAC1 in diabetic cardiomyopathy. Sci Rep. 6:363402016. View Article : Google Scholar : PubMed/NCBI
9	Wang S, Xu H, Zou L, Xie J, Wu H, Wu B, Yi Z, Lv Q, Zhang X, Ying M, et al: LncRNA uc.48+ is involved in diabetic neuropathic pain mediated by the P2X3 receptor in the dorsal root ganglia. Purinergic Signal. 12:139–148. 2016. View Article : Google Scholar : PubMed/NCBI
10	Yan R, Wang K, Peng R, Wang S, Cao J, Wang P and Song C: Genetic variants in lncRNA SRA and risk of breast cancer. Oncotarget. 7:22486–22496. 2016. View Article : Google Scholar : PubMed/NCBI
11	Chen G, Yu D, Nian X, Liu J, Koenig RJ, Xu B and Sheng L: LncRNA SRA promotes hepatic steatosis through repressing the expression of adipose triglyceride lipase (ATGL). Sci Rep. 6:355312016. View Article : Google Scholar : PubMed/NCBI
12	Long J, Zhu N, Zhang CJ, Liu C, Tuo QH, Liao DF and Qin L: LncRNA-SRA promotes vascular smooth muscle cells proliferation via MEK/ERK/CREB signaling pathway. Atheroscler Suppl. 32:113–121. 2018. View Article : Google Scholar
13	Rivard A and Andrés V: Vascular smooth muscle cell proliferation in the pathogenesis of atherosclerotic cardiovascular diseases. Histol Histopathol. 15:557–571. 2000.PubMed/NCBI
14	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
15	Ahlqvist E, Van Zuydam NR, Groop LC and McCarthy MI: The genetics of diabetic complications. Nat Rev Nephrol. 11:277–287. 2015. View Article : Google Scholar : PubMed/NCBI
16	Sun SF, Tang PMK, Feng M, Xiao J, Huang XR, Li P, Ma RCW and Lan HY: Novel lncRNA Erbb4-IR promotes diabetic kidney injury in db/db mice by targeting miR-29b. Diabetes. 67:731–744. 2018. View Article : Google Scholar : PubMed/NCBI
17	Zhuo C, Jiang R, Lin X and Shao M: LncRNA H19 inhibits autophagy by epigenetically silencing of DIRAS3 in diabetic cardiomyopathy. Oncotarget. 8:1429–1437. 2017. View Article : Google Scholar : PubMed/NCBI
18	Cao B, Liu N and Wang W: High glucose prevents osteogenic differentiation of mesenchymal stem cells via lncRNA AK028326/CXCL13 pathway. Biomed Pharmacother. 84:544–551. 2016. View Article : Google Scholar : PubMed/NCBI
19	Gong Y, Zhu Y, Zhu B, Si X, Heng D, Tang Y, Sun X and Lin L: LncRNA MALAT1 is up-regulated in diabetic gastroparesis and involved in high-glucose-induced cellular processes in human gastric smooth muscle cells. Biochem Biophys Res Commun. 496:401–406. 2018. View Article : Google Scholar : PubMed/NCBI
20	Güemes M, Rahman SA and Hussain K: What is a normal blood glucose? Arch Dis Child. 101:569–574. 2016. View Article : Google Scholar : PubMed/NCBI
21	Brownlee M and Hirsch IB: Glycemic variability: A hemoglobin A1c-independent risk factor for diabetic complications. JAMA. 295:1707–1708. 2006. View Article : Google Scholar : PubMed/NCBI
22	Liebl A, Mata M and Eschwege E: Evaluation of risk factors for development of complications in type II diabetes in Europe. Diabetologia. 45 (Suppl 1):S23–S28. 2002. View Article : Google Scholar